Research Nester released a report titled “Prophylactic HIV Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global prophylactic HIV drugs market in terms of market segmentation by drug, by dosage form, by distribution channel and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Prophylactic HIV drugs mainly consist of post exposure prophylaxis (PEP) drugs which are taken after the possible exposure of HIV and pre exposure prophylaxis (PrEP) drugs which are taken before the exposure. The market for prophylactic HIV drugs is anticipated to observe a significantly high CAGR during the forecast period, i.e., 2019-2027. The market is segmented by drug, by dosage form, by distribution channel and by region, out of which, the dosage form segment is further bifurcated into oral dosage forms and topical dosage forms. Based on dosage forms, the oral segment is anticipated to hold the largest share in the market on account of easy availability of oral forms of HIV drugs in the form of tablets and capsules at pharmacies and online.
The largest share in prophylactic HIV drugs market is anticipated to be held by the market in North America region. This can be attributed to the rising advancements in medical industry in the region along with the development of novel drugs and therapies for HIV prevention in the region. On the other hand, the market in Europe is estimated to hold a significant share as a result of growing demand for preventive measures for HIV. The market in Asia-Pacific region is estimated to grow at a significant rate on account of growing prevalence of HIV among the population along with healthcare measures for improvement of the industry and prevention of HIV by the government.
Beneficial Properties of Prophylactic HIV Drugs to Boost the Market Growth
Since prophylactic HIV drugs significantly reduce the risk of being infected by HIV, they are increasingly being used by people. Moreover, these drugs also control the transmission of HIV and further raise the demand in the market. However, the market is estimated to witness hindrance as a result of strict government policies regarding the regulation and approval of these drugs.
This report also provides the existing competitive scenario of some of the key players of the global prophylactic HIV drugs market which includes company profiling of Gilead Sciences, Inc. (GILD), Merck Sharp & Dohme Corp. (MRK), Mylan Pharmaceuticals (MYL), Cipla Inc. (CIPLA), Bristol-Myers Squibb Company (BMY) and Genentech, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global prophylactic HIV drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
